Table 3.
The relationship of mortality and initiation timing of HAART among HIV-TB co-infected patients*
| Total (n = 218) | Death (N = 52, 24%) | Hazard ratio (95% CI) | Adjusted HR $ (95% CI) | Adjusted HR # (95% CI) | |
|---|---|---|---|---|---|
| Age at TB diagnosis (per 5-year increase) |
|
|
1.14 (1.03-1.27) |
1.12 (1.01-1.25) |
1.13 (0.97-1.32) |
| CD4 count at TB diagnosis (per 50-cell increase) |
|
|
0.94 (0.83-1.06) |
0.81 (0.71-0.92) |
0.79 (0.60-1.05) |
| IRIS |
57 |
5 (8.8%) |
0.26 (0.10-0.65) |
0.36 (0.14-0.97) |
0.36 (0.13-0.95) |
| HAART initiation timing during anti-TB therapy | |||||
| No HAART |
36 |
23 (63.9%) |
1 |
1 |
|
| 0–15 days |
110 |
19 (17.3%) |
0.17 (0.09-0.31) |
0.14 (0.07-0.27) |
0.97 (0.34-2.70) |
| 16–30 days |
34 |
5 (14.7%) |
0.14 (0.05-0.36) |
0.10 (0.04-0.28) |
0.69 (0.19-2.49) |
| 31–60 days |
19 |
0 (0%) |
– |
– |
– |
| >60 days | 19 | 5 (26.3%) | 0.25 (0.10-0.67) | 0.14 (0.05-0.39) | 1 |
Abbreviations: HAART highly active antiretroviral therapy, IRIS Immune reconstitution inflammatory syndrome.
*Only enrolled cases with available CD4+ lymphocyte count. HBV co-infection, HCV co-infection and TB location were analyzed initially but the p value was greater than 0.15 and was not included for multivariate analysis and not shown in the table.
$ Adjusted for age at TB diagnosis, CD4 + lymphocyte count, IRIS and HAART initiation timing (use no HAART as reference).
#Excluded cases who did not start HAART during TB treatment and adjusted for age at TB diagnosis, CD4+ lymphocyte count, IRIS and HAART initiation timing (use after 60 day as reference).